Scientists test 'One-Two Punch' to make Cancer-Killing cell therapy last longer

This study is for people with a hard-to-treat type of aggressive B-cell lymphoma that has come back or hasn't responded to other treatments. Researchers want to see if giving two additional drugs (chidamide and a PD-1 inhibitor) as maintenance therapy after a person's own immune cells are engineered to fight cancer (CAR-T therapy) can help keep the cancer away longer and improve survival. They are enrolling about 30 patients to test this combined approach.